Pipelines

The company continues to be oriented towards innovation and internationalization, increasing investments in research and development and the recruitment of scientific research personnesl. Through independent research and development, cooperative development, licensing, deep incubation, and other diversification a multi-level cooperation model,that enriches the pipeline of innovative products, enhances the research and development and clinical capabilities of new drugs, and accelerates the development and transformation of innovative technologies and products has been set up.

Drug Target of action Indication Dosage form Target validation Leader confirmation Non-clinical study IND Clinical Phase I Clinical Phase II Clinical Phase III Pre-NDA NDA

Pelecanam

(PL-5)

Bacterial cell membrane Secondary wound infection (China) Spray

 

Diabetic foot infection (USA) Spray

 

PL-18 Bacterial/fungal cell membrane Fungal vaginitis (Australia) Suppository

 

Fungal vaginitis (China) Suppository

 

PL-3301 Bacterial/fungal cell membrane Oral candidiasis Oral gel

 

Acute bacterial skin and skin structure infections(ABSSSI) Hydrogel nanoneedle

 

Pulmonary infection Inhalant

 

PL-4902 Bacterial cell membrane Systemic/pulmonary infection Injection

 

PL-AC-333 BKR Antagonists (Undisclosed) Colorectal Oral/Injection
(Small molecule)

 

PL-AC-343 Solid tumor Oral/Injection
(Small molecule)

 

PL-AC-328 Gastrointestinal cancer Oral/Injection
(Small molecule)

 

PL-52
PROTAC
Undisclosed Three negative breast cancer, colorectal cancer Oral/Injection
(Small molecule)